Background: Pralsetinib is a potent, selective RET inhibitor targeting oncogenic RET alterations. As part of the global, phase 1/2 ARROW trial (NCT03037385), the efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) were evaluated.
Methods: Adult patients with advanced, RET fusion-positive NSCLC with or without prior platinum-based chemotherapy were enrolled into two cohorts receiving 400-mg once-daily oral pralsetinib. Primary end points were objective response rates assessed by blinded independent central review and safety.
Results: Of 68 patients enrolled, 37 had received prior platinum-based chemotherapy (48.6% with ≥3 prior systemic regimens) and 31 were treatment-naïve. As of March 4, 2022 (data cutoff), of the patients with measurable lesions at baseline, a confirmed objective response was observed in 22 (66.7%; 95% confidence interval [CI], 48.2-82.0) of 33 pretreated patients, including 1 (3.0%) complete response and 21 (63.6%) partial responses; and in 25 (83.3%; 95% CI, 65.3-94.4) of 30 treatment-naïve patients, including two (6.7%) complete responses and 23 (76.7%) partial responses. Median progression-free survival was 11.7 months (95% CI, 8.7-not estimable) in pretreated patients and 12.7 months (95% CI, 8.9-not estimable) in treatment-naïve patients. The most common grade 3/4 treatment-related adverse events in 68 patients were anemia (35.3%) and decreased neutrophil count (33.8%). Eight (11.8%) patients discontinued pralsetinib because of treatment-related adverse events.
Conclusion: Pralsetinib showed robust and durable clinical activity with a well-tolerated safety profile in Chinese patients with RET fusion-positive NSCLC.
Clinical Trial Registration: NCT03037385.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.34897 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Selpercatinib in Chinese patients with -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial.
Ther Adv Med Oncol
January 2025
Statistical Sciences, Eli Lilly and Company, Shanghai, China.
Background: Selpercatinib is approved for the treatment of -fusion-positive non-small-cell lung cancer (NSCLC).
Objective: We present a final update on LIBRETTO-321 to enhance the understanding of long-term efficacy and safety in Chinese patients.
Design: This open-label, multicenter, phase II study included patients with advanced -altered solid tumors.
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review.
Ther Adv Med Oncol
December 2024
Medical Oncology Department, Hospital Clinic of Barcelona, Calle Villarroel 170, Barcelona 08036, Spain.
Article Synopsis
- This systematic review investigates the effects of sex on treatment outcomes in patients with non-small cell lung cancer (NSCLC) who have specific gene fusions and are treated with targeted therapies.
- The review analyzed data from 10 studies focusing on progression-free survival (PFS) and 3 studies examining overall survival (OS), finding no significant differences in survival between male and female patients receiving ALK inhibitors.
- The lack of available data regarding sex-based differences in response rates and adverse events highlights a critical gap in understanding how sex may influence treatment effectiveness and safety in targeted therapy for NSCLC.
Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
Oral Oncol
December 2024
Department of Thyroid Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Electronic address:
Background: Locally advanced papillary thyroid carcinoma (PTC) with RET fusion-positive poses significant challenges for surgical resection due to tumor invasion into critical structures. Neoadjuvant targeted therapies are a promising approach to reduce the tumor burden and improve the resectability. Selperctinib, a RET kinase inhibitor, has been approved for the treatment of advanced or metastatic RET-altered thyroid cancer.
View Article and Find Full Text PDFCytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib.
J Oncol Pharm Pract
December 2024
Michigan Medicine, Clinical Pharmacist Specialist, Inpatient Hematology, University of Michigan, Ann Arbor, MI, USA.
Introduction: Mutated rearranged during transfection (RET) kinase is found in approximately 1-2% non-small-cell lung cancer (NSCLC) patients. These patients are typically younger, non-smokers, and have non-squamous histology. Pralsetinib is a novel RET inhibitor that showed promising efficacy and tolerability in the ARROW trial.
View Article and Find Full Text PDFA real-world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib.
Front Oncol
November 2024
Department of Pediatric Intensive Care Unit, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Background: Pralsetinib, a selective oral inhibitor of rearranged during transfection (RET) fusion proteins and oncogenic RET mutants, has shown significant efficacy in treating RET fusion-positive non-small cell lung cancer and thyroid cancer. However, since pralsetinib was approved in the United States in September 2020, there have been limited reports of post-marketing adverse events (AEs). In this study, we aimed to analyze the AE signals with pralsetinib on the basis of the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to provide instructions in clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!